NASDAQ$SRDX
Surmodics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported an increase in revenue and positive GAAP and non-GAAP EPS compared to the prior-year period.
Surmodics reported an 8% increase in total revenue to $28.0 million for the fourth quarter of fiscal year 2023, with GAAP EPS of $0.47 and non-GAAP EPS of $0.53. The company's revenue performance exceeded its guidance range, driven by contributions from both business segments. Surmodics is strategically positioned for future success with a portfolio of key product growth catalysts and a healthy balance sheet.
- Total revenue increased by 8% year-over-year to $28.0 million.
- GAAP diluted EPS was $0.47, compared to $(1.06) in the prior-year period.
- Non-GAAP diluted EPS was $0.53, compared to $(0.26) in the prior-year period.
- Launched Preside™ medical device coating technology.
Headline financials
Revenue & EPS history
Surmodics · Revenue · Quarterly
$28M
Revenue by segment
Surmodics · $28M total across 2 segments · Q4 2023
- Medical Device$21M+7.9%75.2%
- In Vitro Diagnostics$6.93M+6.8%24.8%
Forward guidance
Surmodics expects fiscal 2024 total revenue to range from $116 million to $121 million, representing a decrease of (13)% to (9)% compared to fiscal 2023. The company expects fiscal 2024 GAAP diluted loss per share to range from $(1.55) to $(1.20). Non-GAAP diluted loss per share in fiscal 2024 is expected to range from $(1.32) to $(0.97).
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports
+1.4%
Avg return
Earnings day
+3.0%
Avg return
5 days after
+6.9%
Avg return
30 days after
59%
37 / 63 earnings
Positive
+34.5%
Q2 2024
Best reaction
-13.1%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +0.6% | +8.5% | -8.0% | |
| Q2 2025 | -1.5% | +2.5% | +7.6% | |
| Q1 2025 | -4.1% | -4.5% | -7.3% | |
| Q4 2024 | +2.0% | +2.3% | +6.2% | |
| Q3 2024 | -0.5% | -1.2% | -4.5% | |
| Q2 2024 | +34.5% | +26.5% | +64.1% | |
| Q1 2024 | -9.8% | -13.0% | -9.6% | |
| Q4 2023 | +1.0% | — | — | |
| Q3 2023 | +4.7% | — | — | |
| Q2 2023 | -2.4% | — | — | |
| Q1 2023 | +4.1% | — | — | |
| Q4 2022 | -3.0% | — | — | |
| Q3 2022 | -7.8% | — | — | |
| Q2 2022 | -1.2% | — | — | |
| Q1 2022 | -11.0% | — | — | |
| Q4 2021 | -11.4% | — | — | |
| Q3 2021 | +3.7% | — | — | |
| Q2 2021 | -5.4% | — | — | |
| Q1 2021 | +15.1% | — | — | |
| Q4 2020 | -2.1% | — | — | |
| Q3 2020 | +0.5% | — | — | |
| Q2 2020 | +3.4% | — | — | |
| Q1 2020 | +6.6% | — | — | |
| Q4 2019 | -13.1% | — | — | |
| Q3 2019 | +13.7% | — | — | |
| Q2 2019 | +0.6% | — | — | |
| Q1 2019 | +17.0% | — | — | |
| Q4 2018 | -11.5% | — | — | |
| Q3 2018 | +11.2% | — | — | |
| Q2 2018 | +7.2% | — | — | |
| Q1 2018 | -0.4% | — | — | |
| Q4 2017 | +0.2% | — | — | |
| Q3 2017 | +1.8% | — | — | |
| Q2 2017 | -7.9% | — | — | |
| Q1 2017 | +1.4% | — | — | |
| Q4 2016 | -6.2% | — | — | |
| Q3 2016 | +8.9% | — | — | |
| Q2 2016 | +14.8% | — | — | |
| Q1 2016 | +8.3% | — | — | |
| Q4 2015 | -2.4% | — | — | |
| Q3 2015 | +9.8% | — | — | |
| Q2 2015 | -2.6% | — | — | |
| Q1 2015 | +3.6% | — | — | |
| Q4 2014 | -3.6% | — | — | |
| Q3 2014 | +2.1% | — | — | |
| Q2 2014 | -4.6% | — | — | |
| Q1 2014 | +7.8% | — | — | |
| Q4 2013 | -3.6% | — | — | |
| Q3 2013 | +10.6% | — | — | |
| Q2 2013 | -6.9% | — | — | |
| Q1 2013 | +1.6% | — | — | |
| Q4 2012 | +0.9% | — | — | |
| Q3 2012 | +10.0% | — | — | |
| Q2 2012 | -1.8% | — | — | |
| Q1 2011 | -1.4% | — | — | |
| Q1 2012 | -1.0% | — | — | |
| Q4 2011 | +1.6% | — | — | |
| Q4 2009 | +1.6% | — | — | |
| Q2 2011 | +1.6% | — | — | |
| Q3 2010 | +1.3% | — | — | |
| Q4 2010 | +1.3% | — | — | |
| Q3 2011 | +1.3% | — | — | |
| Q2 2010 | +1.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro